<DOC>
	<DOC>NCT01412060</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia.</brief_summary>
	<brief_title>Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients who have provided informed consent prior to any study specific procedures Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSMIVTR) criteria for schizophrenia as confirmed by the Patients with normal physical examination, laboratory, vital signs,and/ or ECG Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 Positive and Negative Syndrome Scale (PANSS) total score greater than or equal to 70 and less than or equal to 120 at Visit 1 and Visit 2 Negative serum Bhuman chorionic gonadotropin (BhCG) pregnancy test (applies to female patients of childbearing potential only) Body mass index between 18 and 40kg/m2, inclusive Patients currently meeting DSMIVTR criteria for schizoaffective disorder, schizophreniform disorder, bipolar I and II and known or suspected borderline or antisocial personality disorder or other DSMIVTR axis II disorders Patients in their first episode of Psychosis Treatmentresistant schizophrenia over the last 2 years Positive result from the blood alcohol test or from the urine drug screen for any prohibited medication At imminent risk of injuring self or others or causing significant damage to property Suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic Disorder</keyword>
</DOC>